Psychopharmacology and Psychiatry Updates GLP-1 Agonists vs. Antipsychotic Weight Gain
12 snips
Jan 21, 2026 
Oliver Freudenreich, M.D., a psychiatrist specializing in clinical psychopharmacology, discusses the groundbreaking potential of GLP-1 agonists in combating weight gain from antipsychotics. He explores the prevalence and associated health risks of this issue, noting the shortcomings of traditional weight management strategies. Delving into mechanisms, he highlights GLP-1's effects on satiety and glucose metabolism. With insights on clinical applications, he emphasizes the urgency of integrating these treatments while continuing essential research.
AI Snips
Chapters
Transcript
Episode notes
Patient Example: Olanzapine Weight Gain
- A 32-year-old woman with schizophrenia gained 35 pounds on olanzapine and considered stopping the drug.
- This clinical vignette frames the dilemma of balancing psychiatric stability against antipsychotic weight gain.
Weight Gain Is Clinically Critical
- Weight gain from antipsychotics is nearly universal and drives nonadherence.
- It also causes major medical risks like diabetes, sleep apnea, and premature cardiovascular death.
GLP-1 Agonists Offer Greater Weight Loss
- Metformin reduces metabolic risk but does not reliably produce weight loss.
- Newer GLP-1 agonists cause substantial weight loss and improve glycemic control.